Earlier today, VYNE Therapeutics Inc (NASDAQ: VYNE) released new preclinical data showing the positive effect of its VYN202 in preclinical models of psoriasis and rheumatoid arthritis.
VYNE expects to submit its IND for VYN202 by year-end 2023 and commence a first-in-human Phase 1a single ascending dose/multiple ascending dose trial in the first quarter of 2024.
If successful, VYNE anticipates commencing Phase 1b trials in moderate-to-severe plaque psoriasis and moderate-to-severe adult-onset rheumatoid arthritis in the second half of 2024.
VYNE Therapeutics also announced private placement financing Full story available on Benzinga.com